A Prescription Audit of Inpatient Department of Super Speciality Hospital in National Capital Region of India

June 7, 2023 updated by: Satyam Suman, Kakatiya University

A Prescription Audit of Inpatient Department of National Accreditation Board for Hospitals and Healthcare Providers Approved Super Speciality Hospital in National Capital Region of India

Prescription auditing is the art to check the detailing, compatibility and performance of the generated prescription from the physician to the pharmacist and patient, by means of the WHO checklist for prescription auditing. An audit is defined as the review and evaluation of the healthcare procedures and documentation to compare the quality of care provided, with accepted standards.

In this study, we will collect In-patient prescriptions from Fortis Hospital. And it will be evaluated for 13 list out parameters i.e Hospital unique ID, patient name, age, sex, weight, date of consultation, cleanliness and legibility, brief history, allergies, clinical examination, presumptive or definite diagnosis, medicine prescribed by generic name, dose, duration, history of a previous adverse event, appropriate abbreviations used, drug-drug interaction, drug duplication, doctor name, registration number and signature. The study is analyzed by Statistical Process Control (SPC).

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Aim of the study:

The aim of the study is to evaluate the quality of the prescription provided to the inpatient.

Objectives of the study:

To study the quality of good prescription In minimization of prescription errors and medication errors Also to comply with good clinical practice Enhancement of patient safety In the maintenance of rational prescribing To study the quality of care provided by the hospital to the patient

Plan of study:

To select the patient based on inclusion and exclusion criteria To collect the information from IP prescription and drug chart To identify prescribing errors and medication error To study the management of good prescription

Methodology:

Study Sites: Fortis Hospital, Noida, Uttar Pradesh (INDIA) Study Design: Observational cohort study Study Duration: 2 months (March, 2023 and May, 2023)

Study Sites: Fortis Hospital, Noida, Uttar Pradesh (INDIA) Study Design: Observational cohort study Study Duration: 2 months (March, 2023 and May, 2023)

Subject Eligibility:

  1. Inclusion Criteria Participants who are willing to participate Participants who are admitted in the in-patient department Participants admitted during the study period Participants who have a prescription which is legible and complete
  2. Exclusion Criteria Participants who are unwilling to provide the required information Participants who are not admitted the in-patient department Participants whose prescription is not legible and competent
  3. Source of the data: Review of In-patient prescription

Sample Size:

300 prescriptions

Study Type

Observational

Enrollment (Actual)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Uttar Pradesh
      • Noida, Uttar Pradesh, India, 201301
        • Fortis Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Select the patient based on inclusion and exclusion criteria Collect the information from IP prescription and drug chart Identify prescribing errors and medication error To study the management of good prescription

Description

Inclusion Criteria:

  • Participants who are willing to participate
  • Participants who are admitted in the in-patient department
  • Participants admitted during the study period
  • Participants who have a prescription which is legible and complete

Exclusion Criteria:

  • Participants who are unwilling to provide the required information
  • Participants who are not admitted the in-patient department
  • Participants whose prescription is not legible and competent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Compliance
Prescription properly filled for specific parameters
Prescription data collection
Non Compliance
Prescription is not filled with specific parameters
Prescription data collection
Not available - NA
Prescription does not contain specific data
Prescription data collection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage prescription
Time Frame: March 2023 and May 2023
Prescription filled for specific parameter
March 2023 and May 2023

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2023

Primary Completion (Actual)

May 28, 2023

Study Completion (Actual)

May 28, 2023

Study Registration Dates

First Submitted

May 28, 2023

First Submitted That Met QC Criteria

June 7, 2023

First Posted (Actual)

June 8, 2023

Study Record Updates

Last Update Posted (Actual)

June 8, 2023

Last Update Submitted That Met QC Criteria

June 7, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • FORTIS/IEC/2023/MAR/PA02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Review of In-patient Prescription

Clinical Trials on Prescription data collection

3
Subscribe